Developmental Funds

发展基金：摘要 南卡罗来纳医科大学霍林斯癌症中心利用癌症 中心支持补助金(CCSG)发展基金，用于支持其促进青少年发展的战略计划 研究人员、团队科学、翻译和临床研究，以及对战略性教师招聘的支持。 在本项目期间，共发放了633,635美元的CCSG发展资金用于试点 资助九个项目的研究经费。包括CCSG基金在内，HCC总共投资了270万美元 2013-2018年间获得的试点研究基金，可直接与26美元的成功获奖挂钩 100万美元的校外多年赠款资金。这是CCSG投资的近10倍收益 美元。此外，CCSG发展基金还支持招聘三名新聘教员 支持扩大在癌症生物学(CB)、发展性癌症方面的科学专门知识 治疗学(DCT)和癌症免疫学(CI)计划。J.Alan Diehl，博士兼生物化学教授 和分子生物学担任SmartState脂质组学和病理生物学教授。迪尔 2014年从宾夕法尼亚大学招聘到MUSC担任BASIC副主任 科学。他的研究目前由一台NCI R01和三台NCI P01资助。阿南德·梅塔，博士和 细胞和分子药理学教授和SmartState蛋白质组生物标志物捐赠主席是 2016年从德雷塞尔大学应聘到马萨诸塞州州立大学。梅塔的研究目前由NCI U01和 R01。卡斯滕·克里格，博士，微生物学和免疫学助理教授，2017年加入MUSC 来自苏黎世大学。他在飞行时间(CyTOF)单细胞细胞术方面的专长被认为是 癌症免疫学计划的优先重点领域。克里格现在正在建立一个技术平台 肝细胞癌的流式细胞术和细胞分选(FCCS)共享用于高维分析的质量资源 细胞学或传统的流式细胞仪和高维分选用于肝细胞癌研究者。在下一个 在项目期间，HCC要求每年602,250美元的发展资金，占整个直接癌症的27% 中心支持拨款申请。这些资金将用于实现以下具体目标：1)奖励试点 为肝癌研究人员提供研究资金，以促进团队科学、高风险/高回报想法和临床前 和临床概念；2)投资新的教师创业方案，以支持肝细胞癌六年战略计划； 以及3)每年为两名早期临床研究人员提供高达20%的支持，他们将被指控 开发由研究人员发起的创新试验。

DEVELOPMENTAL FUNDS: SUMMARY The Hollings Cancer Center (HCC) at the Medical University of South Carolina (MUSC) utilizes the Cancer Center Support Grant (CCSG) developmental funds to fuel its strategic plans for advancement of junior investigators, team science, translational and clinical research, and support of strategic faculty recruitments. During the current project period a total of $633,635 of CCSG developmental funds were distributed for pilot research funding in support of nine projects. Including the CCSG funds, HCC invested a total of $2.7 million in pilot research funds awarded between 2013-2018, which can be directly linked to the successful award of $26 million in extramural, multi-year grant funding. This is a nearly 10-fold yield from the investment of CCSG dollars. In addition, CCSG developmental funds supported the recruitment of three new faculty recruits supporting the expansion of scientific expertise in the Cancer Biology (CB), Developmental Cancer Therapeutics (DCT), and Cancer Immunology (CI) Programs. J. Alan Diehl, PhD and Professor of Biochemistry & Molecular Biology holds the SmartState Endowed Professor of Lipidomics and Pathobiology Chair. Diehl was recruited to MUSC in 2014 from the University of Pennsylvania to serve as the Associate Director of Basic Science. His research is currently funded by an NCI R01 and three NCI P01s. Anand Mehta, PhD and Professor of Cell & Molecular Pharmacology and SmartState Endowed Chair of Proteomic Biomarkers was recruited to MUSC in 2016 from Drexel University. Mehta’s research is currently funded by an NCI U01 and R01. Carsten Krieg, PhD is Assistant Professor of Microbiology & Immunology and recruited to MUSC in 2017 from the University of Zurich. His expertise in single cell cytometry by time of flight (CyTOF) was identified as a priority focal area for Cancer Immunology Program. Krieg is now building a technology platform within the HCC’s Flow Cytometry & Cell Sorting (FCCS) Shared Resource for high dimensional analysis using mass cytometry or conventional flow cytometers and high dimensional sorting for HCC investigators. In the next project period, the HCC requests $602,250 per year in developmental funds, 27% of the overall direct Cancer Center Support Grant request. These funds will be utilized in meeting the following specific aims: 1) Award pilot research funding to HCC investigators to promote team science, high risk/high reward ideas, and pre-clinical and clinical concepts; 2) Invest in new faculty start-up packages in support of the HCC six-year strategic plan; and 3) Support up to 20% effort for two early-stage clinical investigators annually who will be charged with developing innovative investigator-initiated trials.